Reports Q4 revenue $7.02M, ones estimate $7.77M. The company said, “We are very excited to see objective responses in heavily pre-treated, checkpoint-experienced head and neck cancer patients, a setting with high unmet medical need, with MT-6402. We are seeing evidence of monotherapy activity of long duration and in patients refractory to checkpoint therapy through a novel mechanism of tumor microenvironment remodeling. We believe these data demonstrate a new and potentially best-in-class approach to targeting the PD-1-PD-L1 axis.. MT-8421 is currently in dose escalation as a novel direct cell-kill approach targeting CTLA-4 to potently deplete Tregs in the tumor microenvironment. Through the first dose cohort, we are already seeing promising and differentiate pharmacodynamic effects including dramatic Treg depletion in patients.” As of December 31, 2023, Molecular’s unrestricted cash and cash equivalents totaled $11.5M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTEM:
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
- Molecular Templates Inc Raises Funds for Clinical Studies
- Molecular Templates announces $9.5M private placement
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
- Two new option listings and option delistings on March 25th